Introduction {#s1}
============

The pleotropic cytokine interleukin-6 (IL-6) is involved in a variety of central nervous system (CNS) pathologies including injury, infection, and neurodegeneration (Erta et al., [@B26]). Its classification as either protective or destructive within the CNS continues to be highly contested. Pre-treatment with IL-6 prevents apoptosis in neural cells exposed to a number of physiological stressors *in vitro*, supporting the idea that IL-6 is neuro-protective (Yamada and Hatanaka, [@B70]; Sappington et al., [@B57]; Spittau et al., [@B61]; Fang et al., [@B27]; Chucair-Elliott et al., [@B14]). In animal models of CNS disease, loss of IL-6 leads to an overall reduction in the neuroinflammatory response, including reduced expression of other inflammatory cytokines and diminished glial reactivity (Penkowa et al., [@B52], [@B49], [@B51]; Clark et al., [@B15]; Cardenas and Bolin, [@B12]). Interestingly, the effect on neuronal health is variable, as studies suggest that IL-6 signaling promotes both viability (Yamada and Hatanaka, [@B70]; Loddick et al., [@B43]; Zhong et al., [@B73]; Clark et al., [@B15]; Cardenas and Bolin, [@B12]; Inomata et al., [@B35]; Penkowa et al., [@B50]; Sappington et al., [@B57]; Spittau et al., [@B61]; Fang et al., [@B27]; Leibinger et al., [@B41]; Chucair-Elliott et al., [@B14]) and dysfunction (Campbell et al., [@B11]; Bluthe et al., [@B3]; Sparkman et al., [@B60]; Mukaino et al., [@B47]; Burton et al., [@B9], [@B8]; Burton and Johnson, [@B7]) depending on the model of CNS injury. IL-6 mRNA and protein are upregulated near retinal ganglion cells (RGCs) and their axons in rodent models of glaucoma (Sappington and Calkins, [@B55]; Chidlow et al., [@B13]; Sims et al., [@B59]; Wilson et al., [@B69]). Glaucoma is a neurodegenerative disease characterized by RGC axonopathy and associated with both advanced age and elevated intraocular pressure (IOP) (Calkins, [@B10]). Like elsewhere in the CNS, the role of IL-6 in RGC axonopathy is unclear. Application of recombinant IL-6 to RGCs *in vitro* prevents pressure-induced apoptosis (Sappington et al., [@B57]). Similarly, IL-6 appears to protect RGCs and enhance axon regeneration following optic nerve crush (Leibinger et al., [@B41], [@B40]). In contrast, other studies indicate that IL-6 deficiency protects RGCs in models of glutamate excitotoxicity and optic nerve crush (Fisher et al., [@B28]).

To better elucidate the impact of IL-6 signaling on RGC axonopathy in glaucoma, we comprehensively examined and compared optic nerve morphology, visual acuity, active axonal transport, and retinal glial reactivity in IL-6 deficient (*IL-6*-/-) and wildtype (WT) mice with 8 weeks of unilateral or bilateral microbead-induced glaucoma (microbead occlusion model). Together, our data indicate that IL-6 deficiency mitigates glaucoma-induced deficits in visual function and optic nerve structure without improvement in axon transport or reduction in microglia reactivity. This suggests that IL-6 may play specific role in the progression of RGC axonopathy from functional deficits to structural degeneration.

Materials and methods {#s2}
=====================

Animals
-------

Seven to nine month old male and female *IL-6*-/- mice (B6;129S2-*IL6*^*t*m1kopf^/J) and respective genomic controls (B6;129SF2/J) were used for all experiments. *IL-6*-/- mice contain a neomycin selection cassette in exon 2 of the IL-6 gene preventing transcription of the mRNA product (Kopf et al., [@B38]). Founder mice were obtained from Jackson Laboratories (Bar Harbor, ME) and experimental mice were bred and genotyped in-house using the following primers provided by Jackson Labs: 5′-TTC-CAT-CCA-GTT-GCC-TTC-TTG-G-3′, 5′-TTC-TCA-TTT-CCA-CGA-TTT-CCC-AG-3′ and 5′-CCG-GAG-AAC-CTG-CGT-GCA-ATC-C-3′. Mice were housed in accordance with NIH guidelines and maintained on a 12 h light/dark cycle with *ad libitum* access to standard mouse chow and water. This study was carried out in accordance with the ARVO statement for the use of animals in ophthalmic and vision research and was approved by the IACUC of Vanderbilt University Medical Center.

Induction of ocular hypertension using the microbead occlusion model
--------------------------------------------------------------------

Acute IOP elevation was induced in WT and *IL-6*-/- mice using the microbead occlusion model, as previously described (Sappington et al., [@B56]). For anterograde axonal transport, axon density measurements, and retinal gliosis, mice from both genotypes received a unilateral injection of 1.5 μl (1 × 10^6^ microbeads/mL) of 15 μm polystyrene beads conjugated to an Alexa Fluor 488 chromophore. The contralateral eye served as a surgical control and was injected with an equal volume of saline. For experiments looking at visual acuity and corneal integrity, 7--11 mice from both genotypes received bilateral injections of 1.5 μl microbeads and a separate cohort of mice served as controls and received bilateral injections of an equivalent volume of saline. All mice received two microbead/saline injections 4 weeks apart to raise IOP for a total of 8 weeks. Following IOP elevation, mice were sacrificed by transcardial perfusion of 50 ml of 1X PBS followed by 100 ml of 4% paraformaldehyde. Eye and brain tissue were stored in 4% PFA at 4°C until use.

IOP measurements
----------------

IOP was measured in awake, behaving mice, using a Tonolab rebound tonometer (TonoLab; Reichert, Depew, NY), as previously described (Echevarria et al., [@B24]; Formichella et al., [@B29]; Echevarria et al., [@B23]). Prior to initial injection, mean baseline IOP for each mouse was calculated from approximately 60 individual readings taken over a period of 6 days (10 measurements/day) within a 2 week timeline. Following microbead or saline injections, weekly IOP was determined as the mean of 20--30 measurements, taken over 2--3 days (10 measurements/day) each week for a total of 8 weeks. IOP measurements were taken at the same time of day to remove any effect of circadian rhythm on IOP measurements. To avoid corneal irritation and discomfort, 0.5% proparacaine anesthetic drops (Akorn Inc, Lake Forest, IL), and lubricating eye drops were applied to each eye before and after IOP measurements were taken respectively.

Immunohistochemistry
--------------------

Immunohistochemistry of whole mount retinas was done as previously described (Sims et al., [@B59]; Echevarria et al., [@B24], [@B23]). Primary antibodies against glial fibrillary acidic protein (GFAP, 1:500; Cat\# Z033429-2; DAKO) to label astrocytes, ionized calcium-binding adapter molecule-1 (Iba-1, 1:250; Cat\# 019-19741; WAKO) to label microglia, and β-Tubulin III (TUJ1, 1:500; Cat\#845501; BioLegend) to label RGCs were used. Secondary antibodies were used at a concentration of 1:200 and consisted of donkey α-rabbit attached to either a Rhodamine Red-X (Cat\# 711-295-152; Jackson Immuno Labs) or Alexa-647 (Cat\# 711-605-152; Jackson Immuno Labs) fluorophore.

Fluorescent *In-situ* hybridization
-----------------------------------

Generation of IL-6 probes and FISH in naïve WT and *IL-6*-/- whole mount retina were done as previously described (Crish et al., [@B18]). Probes were made against a nucleotide sequence encompassing exons 2--5 of *IL-6* \[nucleotides 107--651 of (NCBI Ref Seq: [NM_031168.2](NM_031168.2))\]. The transcript inserted into the pGEM-T Easy Vector (Promega, Madison WI) was generated by PCR using primers to IL-6 (forward 5′-ATCCAGTTGCCTTCTTGGGACTGA-3′ and reverse 5′TGGCTAAGGACCAAGACCATCCAA-3′). Following FISH, retinas underwent immunohistochemistry as described above to label RGCs.

Microscopy and image analysis
-----------------------------

Imaging of whole mount retinas was done on an inverted confocal microscope (Olympus FV-1000; Center Valley, PA) through the Vanderbilt University Medical Center Cell Imaging Shared Resource Core. *IL-6* and β-Tubulin III labeling was imaged at 100X, while GFAP and Iba-1 was imaged at 60X. For both groups, 7--9 pseudo-random z-stack images in the mid central/mid-peripheral areas through the ganglion cell (GCL) and nerve fiber layers (NFL) of the retina were acquired using a digital camera and image analysis software (FV-100 ASW; Olympus). GFAP and Iba-1 percent area was calculated using NIS elements AR software (Nikon Instruments, Melville, NY), as previously described (Formichella et al., [@B29]). The area (mm^2^) of the image containing above background signal intensity of Iba-1 or GFAP (See **Figures 6A,B**; red labeling) was calculated and reported as a percentage of the total area of the image. Total area of each image and background signal threshold was equal among all images. Microglia cell density was calculated by counting the number of Iba-1 positive cell somas and dividing the counts by the area of the image.

Anterograde axon transport measurements
---------------------------------------

Anterograde axonal transport capabilities of RGCs were assessed with cholera toxin beta-subunit (CTB) conjugated to a 488 fluorophore, as previously described (Crish et al., [@B19]; Formichella et al., [@B29]; Ward et al., [@B68]; Bond et al., [@B4]). Briefly, mice were given a 1.5--2 μl intravitreal injection of CTB (10 μg/μl in sterile ddH~2~O; Cat\# C-34775, Life Technologies) using a 33 gauge needle attached to a Hamilton syringe under 2.5% isoflurane anesthesia. Five days after CTB injection, mice were sacrificed by transcardial perfusion as described above. To quantify axon transport, whole brains were cryopreserved in 30% sucrose for 24--48 h at 4°C. Using a sliding microtome, 50 μm sections were obtained through the superior colliculus (SC). CTB signal in these sections was imaged *en montage* at 10X, using a Nikon Eclipse T*i* inverted microscope (Nikon Instruments, Melville, NY). Anterograde axonal transport was quantified as previously described (Crish et al., [@B19]). Briefly, the SC from each image was outlined and CTB signal above background was divided by total pixel area to determine the volume of SC with CTB labeling. This value was used to create a colorimetric 2D retinotopic map of CTB transport ranging from 0% (blue) and 100% (red). Intact transport was defined as percent area with CTB signal [\>]{.ul}70% density (red/yellow).

Axon density and nerve area
---------------------------

Axon density was measured in semi-thin sections of optic nerve as previously described (Sappington et al., [@B56]; Ward et al., [@B68]). Briefly, optic nerves were post fixed at least 48 h in 2.5% glutaraldehyde and embedded in epon. Semi-thin (700 nm) cross-sections of optic nerve near the chiasm were stained with 1% p-Phenylenediamine (PPD) and 1% toluidine blue to highlight myelin and glia, respectively. Optic nerve cross-sections were imaged *en montage* at 100X magnification on an upright Olympus Provis AX (Olympus, Melville, NY) microscope. To calculate axon density, a 50 × 50 μm grid mask was placed on the montaged image using NIS elements AR software. The number of axons was manually counted by a blind-observer in 8--10 squares of the grid. Each square counted was equal in area (0.0025 mm^2^). To measure nerve area, the circumference of the nerve was traced in montaged images of optic nerve cross-sections. Nerve area was calculated as the area (mm^2^) within this outline using NIS elements software.

Neurobehavioral visual testing using optomotry
----------------------------------------------

The optokinetic response is a naturally occurring reflex that serves as a functional tool for quantitative analyses of visual system function in mice (Douglas et al., [@B21]). Briefly, each mouse was placed on a platform surrounded by four LCD computer monitors. A sinusoidal grating of alternating white and black bars rotating in either a clock-wise or counter clock-wise fashion was projected on the monitors. Mice able to perceive the moving stimulus produced a reflexive movement of the head in the direction of the stimulus. The visual acuity of each mouse was measured by changing the spatial frequency of the black and white bars. The visual acuity threshold was determined as the highest spatial frequency for which reflexive tracking was noted. The presence of the reflexive head movement was recorded by an observer using a camera mounted above the mouse. Mice were tested for baseline visual acuity threshold 1--2 weeks before microbead/saline injection and 4 and 8 weeks post-initial microbead/saline injection.

Corneal imaging using spectral domain optical coherence tomography (SD-OCT)
---------------------------------------------------------------------------

Mice were anesthetized with a ketamine/xylazine cocktail (80/5 μg/gram of mouse), pupils were dilated with 0.5% Tropicamide, and eyes kept moist with lubricating eye drops. Live volumetric scans of the cornea were obtained using SD-OCT running the Bioptogen ultra-high resolution spectral domain OCT system with cornea bore (Bioptogen, Morrisville, NC). Quantification of injury area was performed using Image J software (National Institute of Health).

### Statistical analysis

Statistical analysis was conducted with SigmaPlot Version 11.1 (Systat Software Inc, San Jose, CA). For baseline and delta baseline IOP comparisons between WT and *IL-6*-/-, a Mann-Whitney Rank Sum test and a One-Way ANOVA with Holm-Sidak *post-hoc* correction was done respectively. For post injection IOP comparisons, a One-Way ANOVA on RANKS with Dunn\'s *post-ho*c correction was done. For corneal wound area measurements, a two-tailed *t*-test was done between WT and *IL-6*-/- mice at each time point. Differences in visual acuity throughout the 8 week experimental time course were assessed with a One-Way Repeated Measures ANOVA between baseline visual acuity, acuity at 4 weeks post initial injection, and 8 weeks post initial injection within each experimental group. Differences between all experimental groups at each time point were assessed with a One-Way ANOVA with Holm-Sidak *post-hoc* correction. Differences in percent baseline visual acuity at 8 weeks between all experimental groups were assessed with a One-Way ANOVA on RANKS with Dunn\'s *post-hoc* correction. All other comparisons were made with a One-Way ANOVA on RANKS with Dunn\'s *post-hoc* correction (percent glia coverage, microglia cell density) or a One-Way ANOVA with Holm-Sidak *post-hoc* correction (SC transport, axon density/nerve area). For all, *p* \< 0.05 were considered statistically significant.

Results {#s3}
=======

IL-6 deficiency does not affect microbead-induced elevations in IOP
-------------------------------------------------------------------

To confirm genetic ablation of IL-6, we conducted PCR to confirm the presence of the neomycin selection cassette in exon 2 of the *IL-6* gene. In all *IL-6*-/- mice used in this study, PCR amplification of exon 2 revealed a 380 bp product in the *IL-6*-/- mouse compared to the 174 bp PCR product in the WT mouse (Figure [1A](#F1){ref-type="fig"}). Loss of *IL-6* mRNA was corroborated using *in situ* hybridization. In a subset of WT and *IL-6*-/- whole mount retina co-immunolabeled with the RGC-specific marker β-Tubulin (TUJ1), labeling for *IL-6* mRNA using an antisense fluorescent *in situ* hybridization (FISH) probe showed robust signal that co-localized to TUJ1+ positive RGCs in WT mice (Figure [1B](#F1){ref-type="fig"}; left). Conversely, anti-sense labeling for *IL-6* mRNA was not detected in *IL-6*-/- mice (Figure [1C](#F1){ref-type="fig"}; left). Similarly, significant *IL-6* mRNA labeling was not detected following incubation with the sense probe in either genotype (Figures [1B,C](#F1){ref-type="fig"}; right). To examine the impact of IL-6 deficiency on the progression of IOP-induced RGC neurodegeneration, we utilized the microbead occlusion model (Sappington et al., [@B56]) of glaucoma to elevate IOP for a total of 8 weeks in WT and *IL-6*-/- mice. Baseline IOP was 4% lower in *IL-6*-/- mice (16.4 +/− 0.79 mmHg), compared to WT mice (17.1 +/− 1.32 mmHg; *p* \< 0.01; Figure [1D](#F1){ref-type="fig"}; left). Microbead injection increased IOP by \~ 20%, as compared to saline-injected controls for both genotypes (WT; *p* \< 0.001, *IL-6*-/-; *p* \< 0.001, Figure [1D](#F1){ref-type="fig"}; right and Figure [1E](#F1){ref-type="fig"}). In accordance with baseline IOP measurements, the mean IOP (mmHg) for both saline- (*p* \< 0.05) and microbead-injected (*p* \< 0.05) was lower in *IL-6*-/- mice than their WT counterparts (Figure [1E](#F1){ref-type="fig"}). However, with respect to baseline IOP, the magnitude of IOP elevation was similar (\~2.5 mmHg) in microbead-injected WT and *IL-6*-/- mice (*p* \> 0.05, Figure [1F](#F1){ref-type="fig"}).

![IL-6 deficiency does not affect magnitude and duration of microbead induced ocular hypertension. **(A)** Representative gel from a PCR confirming the *IL-6*-/- genotype. PCR amplification of exon 2 leads to a PCR product of 380 bp in *IL-6*-/- mice and a 174 bp PCR product in WT mice. No band present in negative control lane. Products were run along a 100 bp ladder. **(B,C)**. Representative 100X confocal image of retinal whole mount from WT **(B)** and *IL-6*-/- mice **(C)** incubated with an anti-sense (AS; left) or sense probe (S; right) against *IL-6* mRNA (right). Signal from AS probe (**B**, green) is found within β-Tubulin (TUJ1) positive RGCs (red) in WT mice **(B)**. No significant signal was present in retinas from *IL-6*-/- mice (**C**; left) or during incubation with sense probe (**B,C**; right). Scale bars = 20 μm. **(D;** left) Boxplot of baseline IOP of WT (white) and *IL-6*-/- (gray) mice from all experimental cohorts prior to microbead/saline injection. Baseline IOP of *IL-6*-/- mice is decreased by 4% compared to baseline IOP of WT mice. (**D**; right) Line plot (mean ± SEM) showing baseline and weekly post saline (circle) or microbead (diamond) IOP in WT (white) or *IL-6*-/- (gray) eyes. Arrows indicate time of saline/microbead injections. Throughout the 8 week experiment, microbead injected eyes from both WT and *IL-6*-/- show a 15--20% increase in IOP compared to baseline measurements and saline injected eyes. **(E)** Bar graph of average IOPs (mean ± SEM) taken post initial microbead (gray) or saline (white) injection in both WT and *IL-6*-/- mice. A significant IOP increase in microbead- injected eyes vs. saline- injected eyes is seen in both genotypes. A genotype specific IOP reduction is seen in both saline- and microbead- injected *IL-6*-/- mice. **(F)** Boxplot showing magnitude of IOP difference in saline (white) and microbead (gray) injected WT and *IL-6*-/- mice compared to baseline measurements. A significant elevation in IOP is present in microbead- injected eyes compared to saline- injected eyes in both genotypes. However, no genotype specific differences in IOP seen. ^\*^*p* \< 0.05. *n* = 26--34 eyes/genotype/condition. Dashed lines in box plot indicate median value.](fnins-11-00318-g0001){#F1}

IL-6 deficiency preserves optic nerve structure following IOP elevation
-----------------------------------------------------------------------

In glaucoma, degeneration of the optic nerve starts at the distal end of the optic nerve and progresses in a distal to proximal fashion (Crish et al., [@B19]). Unlike the distal optic nerve of saline-injected WT mice (Figure [2A](#F2){ref-type="fig"}; top), the distal optic nerve of microbead-injected WT mice presented with signs of structural pathology, including increased glial infiltration and degenerating axon profiles (Figure [2A](#F2){ref-type="fig"}; bottom). This was accompanied by a slight enlargement in nerve area (Figure [2C](#F2){ref-type="fig"}; left) and a 15% decrease in axon density, as compared to saline-injected mice (*p* \< 0.05, Figure [2D](#F2){ref-type="fig"}; left). In contrast, while distal optic nerves from microbead-injected *IL-6*-/- mice presented with some gliosis, no change in degenerating axon profiles were noted (Figure [2B](#F2){ref-type="fig"}). Similarly, there were no measurable changes either in nerve area (Figure [2C](#F2){ref-type="fig"}; right) or myelinated axon density (*p* \> 0.05, Figure [2D](#F2){ref-type="fig"}; right), as compared to saline-injected *IL-6*-/- mice. However, independent of IOP, optic nerves from *IL-6*-/- mice contained approximately \~15% fewer myelinated RGC axons than those from WT mice (*p* \< 0.05, Figure [2D](#F2){ref-type="fig"}).

![IL-6 deficiency mitigates axon degeneration caused by IOP elevation. **(A,B)** Representative 100X montaged optic nerve cross sections from WT **(A)** and *IL-6*-/- **(B)** optic nerves following saline (top) or microbead (bottom) injection. Black box in montaged image (left) corresponds to location of zoomed images highlighting axon and glia (right). IOP elevation results in increased glial infiltration (black arrows) and degenerative axon profiles (white arrow heads) in optic nerves from microbead injected WT, but not *IL-6*-/- mice. **(C)** Bar graph of average (mean ± STDEV) myelinated axon density measurements in WT and *IL-6*-/- mice following saline (white) or microbead (gray) injection. Saline- injected *IL-6*-/- mice show a genotype specific decrease in myelinated axon density compared to saline- injected WT mice. However, microbead- injected WT eyes show a significant 15% decrease in myelinated axon density compared to saline- injected WT eyes, while no difference is seen between microbead- and saline- injected *IL-6*-/- eyes. **(D)** Bar graph of average nerve area (mean ± STDEV) among groups shows no significant difference. ^\*^*p* \< 0.05. *n* = 40--50 density measurements/genotype/group. Scale bars = 50 μm for 100X montaged optic nerves and 10 μm for zoomed images.](fnins-11-00318-g0002){#F2}

IL-6 deficiency does not prevent IOP-induced deficits in anterograde axon transport
-----------------------------------------------------------------------------------

Previous reports indicate that functional deficits in anterograde axon transport along the optic projection precede structural degeneration of RGC axons in glaucoma (Crish et al., [@B19], [@B18]). To measure active anterograde transport in RGC axons, we injected the active uptake, active transport tracer cholera toxin beta subunit (CTB) into the vitreous of *IL-6*-/- and WT mice 8 weeks after the initial microbead or saline injection. We measured anterograde transport of CTB from RGC soma in the retina to RGC terminals in the superior colliculus (SC) by quantifying CTB labeling in serial sections of SC and generating 2D reconstructions of CTB labeling in the SC (Figure [3A](#F3){ref-type="fig"}). In WT mice, 8 weeks of elevated IOP led to a \~50% decrease in CTB transport to the SC, as compared to saline-injected mice (*p* \< 0.001, Figure [3A](#F3){ref-type="fig"}; top, Figure [3B](#F3){ref-type="fig"}; left). Interestingly, in *IL-6*-/- mice, IOP elevation also resulted in a \~50% decrease in CTB transport (*p* \< 0.001, Figure [3A](#F3){ref-type="fig"}; bottom, Figure [3B](#F3){ref-type="fig"}; right). Similar to previously published studies (Crish et al., [@B19]; Lambert et al., [@B39]; Ward et al., [@B68]), these deficits occurred in a sectoral manner, extending from the periphery toward the optic disc in WT and *IL-6*-/- mice (Figure [3A](#F3){ref-type="fig"}). No differences in axon transport were noted between genotype in saline-injected animals (*p* \> 0.05, Figure [3B](#F3){ref-type="fig"}).

![IL-6 deficiency does not alter IOP-dependent deficits in anterograde axon transport. **(A)** Representative coronal sections through the superior colliculus (SC) and respective retinotopic heat maps after 5 days of CTB transport in WT (top) and (bottom) *IL-6*-/- mice. Outlines in coronal sections indicate areas of transport deficits. Dashed lines in map indicate position of coronal section. Density of the CTB signal for heat maps range from 0% (blue) to 50% (green) to 70% (yellow) to 100% (red). Numbered, dashed lines in retinotopic maps indicate the location of respective coronal section and white circles indicate position of the optic disk (OD). Medial (M) and rostral (R) orientations are indicated. **(B)** Bar graph showing average percent intact transport (mean ± STDEV, [\>]{.ul}70% density of CTB signal; red/yellow areas) from SC following saline (white) or microbead (gray) injection in WT (left) and *IL-6*-/- (right) mice. SC from both microbead- injected WT and *IL-6*-/- mice show a \~50% deficit in intact axon transport compared to saline- injected mice. ^\*^*p* \< 0.05. *n* = 5--6 SC/genotype/condition. Scale bars = 500 μm for all images.](fnins-11-00318-g0003){#F3}

IL-6 deficiency preserves visual acuity following IOP elevation
---------------------------------------------------------------

Loss of vision in glaucoma is irreversible and caused by degeneration of RGCs and their axons (Calkins, [@B10]). To ensure detection of any vision loss associated with microbead-induced glaucoma, we performed bilateral injections of microbeads in one cohort of WT and *IL-6*-/- mice. A second cohort received bilateral injections of saline. We measured visual acuity by optomotry every 4 weeks for the duration of the experiment. Over the course of 8 weeks, microbead-injected WT mice exhibited significant depreciation of visual acuity at each time point compared to baseline, resulting in an overall 22% decrease in visual acuity (*p* \< 0.001 for all, Figure [4A](#F4){ref-type="fig"}; gray). However, in saline-injected WT mice, visual acuity did not significantly differ from baseline at either time point (*p* \> 0.05, Figure [4A](#F4){ref-type="fig"}; white). Comparison of visual acuity between saline- and microbead-injected WT mice revealed a significant \~15% decrease in both raw visual acuity (*p* \< 0.05, Figure [4C](#F4){ref-type="fig"}) and percent baseline visual acuity (*p* \< 0.05, Figure [4D](#F4){ref-type="fig"}). In *IL-6*-/- mice, visual acuity dropped 8% with either saline (*p* \< 0.01) or microbeads (*p* \< 0.05), as compared to baseline acuity (Figure [4B](#F4){ref-type="fig"}). However, this initial reduction in visual acuity did not differ between saline- and microbead-injected *IL-6*-/- mice (*p* \> 0.05, Figures [4C,D](#F4){ref-type="fig"}) and remained unchanged between 4 and 8 weeks for both groups (saline: *p* \> 0.05; microbead: *p* \> 0.05; Figure [4B](#F4){ref-type="fig"}). That this slight decrease in visual acuity was noted in both saline- and microbead-injected *IL-6*-/- mice and remained stable for the 8 week experiments suggest that it arises from an IOP-independent influence. No difference in visual acuity was noted between WT and *IL-6*-/- mice at any time point (*p* \> 0.05, Figure [4C](#F4){ref-type="fig"}).

![*IL-6*-/- mice are resistant to IOP-induced deficits in visual acuity. **(A)** Bar graph showing average visual acuity threshold (mean ± SEM) of WT mice at baseline and 4 and 8 weeks post initial saline (white) or microbead (gray) injection. WT mice injected with microbeads show a significant decrease in visual acuity at both 4 weeks and 8 weeks post-injection compared to baseline. **(B)** Bar graph showing average visual acuity threshold (mean ± SEM) of *IL-6*-/- mice at baseline and 4 and 8 weeks post initial saline (white) or microbead (gray) injection. *IL-6*-/- mice injected with either saline or microbeads show a significant decrease in visual acuity at 8 weeks compared to baseline. **(C)** Line graph comparing visual acuity of WT saline (white circle), WT microbead (white diamond), *IL-6*-/- saline (gray circle) and *IL-6*-/- microbead (gray diamond) at each time point. Visual acuity decreases significantly in microbead-injected WT mice compared to saline-injected WT mice. Visual acuity does not differ between saline- and microbead- injected *IL-6*-/- or between genotypes. **(D)** Boxplot of the percent visual acuity remaining at 8 weeks compared to baseline measurements for WT and *IL-6*-/-. WT mice injected with microbeads show a significant decrease in the remaining visual acuity when compared to the saline- injected WT mice. *IL-6*-/- mice injected with microbeads show no difference in the remaining visual acuity when compared to the saline injected *IL-6*-/- cohort. ^\*^*p* \< 0.05, ^\*\*^*p* \< 0.001. *n* = 13--17/group. Dashed lines in boxplot indicate median value of data set.](fnins-11-00318-g0004){#F4}

*IL-6*-/- mice exhibit deficits in corneal wound healing
--------------------------------------------------------

Previous studies indicate *IL-6*-/- mice exhibit deficits in wound healing (Lin et al., [@B42]; McFarland-Mancini et al., [@B46]). As the microbead/saline injections require puncturing of the cornea, we used spectral-domain optical coherence tomography (SD-OCT) imaging to examine whether perturbed healing of the cornea could underlie the reduction in visual acuity noted in both saline and microbead-injected *IL-6*-/- mice. Two weeks following intra-cameral injection of saline or microbeads in WT eyes, SD-OCT imaging revealed complete closure of the epithelial layer and approximately 2/3 closure of the stroma and endothelial layers at the injection site (Figure [5A](#F5){ref-type="fig"}). Quantification of the remaining corneal wound revealed no significant change over the remaining 6 weeks (*p* \> 0.05; Figure [5C](#F5){ref-type="fig"}). In *IL-6*-/- mice, SD-OCT imaging revealed complete closure of the epithelial layer by 2 weeks. However, limited closure of the stroma and endothelial layers was noted (Figure [5B](#F5){ref-type="fig"}). This reduction in stroma and endothelial wound healing was noted throughout the 8 week experiment (Figure [5B](#F5){ref-type="fig"}). Quantification of corneal injury revealed that the area of corneal wound was 2-fold larger in *IL-6*-/- mice than in WT mice at all three time points (*p* \< 0.05; Figure [5C](#F5){ref-type="fig"}). Like WT mice, the area of the corneal wound did not change over the 8 week experiment in *IL-6*-/- (*p* \> 0.05; Figure [5C](#F5){ref-type="fig"}).

![*IL-6*-/- mice present with defects in corneal wound healing following microbead/saline injection.**(A)** Representative images of corneal wounds at 2, 4 and 8 weeks post initial injection in WT mice. Insert (**A;** far left) outlines layers of the cornea. 2 weeks after corneal puncture due to saline or microbead delivery, WT mice left display small gaps in the corneal stroma and endothelium (yellow dotted lines). The size of the injury persists after 4 (middle) and 8 (right) weeks after injury. **(B)** Representative images of corneal wounds at 2, 4, and 8 weeks post injection in *IL-6*-/- mice. *IL-6*-/- mice however, present with significantly larger gaps 2 weeks (left) in the corneal stroma after puncture that also persists at 4 (middle) and 8 (right) weeks after injury. **(C)** Bar graph showing quantification of corneal injury area (mean ± SEM). *IL-6*-/- mice have significantly larger corneal injuries at all time points. Size of the wound area did not change significantly over time in either WT or *IL-6*-/-. ^\*^*p* \< 0.05. *n* = 9 eyes/genotype/group. Scale bars= 100 μm for all images.](fnins-11-00318-g0005){#F5}

IL-6 deficiency enlarges the microglia population in retina
-----------------------------------------------------------

Recent studies suggest that changes in glial reactivity in the retina occur in response to IOP elevation, and impact RGC degeneration in both genomic and inducible models of glaucoma (Martin et al., [@B45]; Sappington and Calkins, [@B54]; Inman and Horner, [@B34]; Bosco et al., [@B5]; Johnson and Morrison, [@B37]; Johnson et al., [@B36]; Echevarria et al., [@B24]; Lye-Barthel et al., [@B44]; Formichella et al., [@B29]; Hines-Beard et al., [@B32]). To determine whether IL-6 deficiency alters glial reactivity associated with RGC axonopathy, we performed a morphological analysis of astrocyte and microglia reactivity in retina. We visualized astrocytes and microglia in whole-mount retina from saline- and microbead- injected WT and *IL-6*-/- mice with immunolabeling against the astrocyte- specific label glial fibrillary acidic protein (GFAP) and the microglia- specific marker ionized calcium binding adaptor molecule (Iba-1). While Iba-1 labels various types of myeloid cells, we selected this marker because (1) 100% of retinal microglia are Iba-1 positive (Bosco et al., [@B6]), (2) Iba-1 expression remains rather stable across activation states compared to other microglia/macrophage markers (Bosco et al., [@B6]) and (3) with the exception of amoeboid microglia, other myeloid cells and microglia can be readily distinguished by morphology. To account for changes in both glia density and hypertrophy/ramification, we quantified the percent of retinal area covered by GFAP+ astrocytes (Figure [6A](#F6){ref-type="fig"}) and Iba-1+ microglia (Figure [6B](#F6){ref-type="fig"}). Our previous work indicates that percent area coverage is a highly reliable measure of reactivity (Formichella et al., [@B29]). GFAP immunolabeling revealed no gross genotype- or IOP-dependent changes in astrocytic morphology (Figure [6C](#F6){ref-type="fig"}). Quantification of astrocyte coverage confirmed no significant change in astrocyte morphology with respect to either IOP or genotype (*p* \> 0.05 for all; Figure [6E](#F6){ref-type="fig"}). In contrast, Iba-1 immunolabeling revealed qualitative changes in microglia that appeared to relate to both genotype and IOP (Figure [6D](#F6){ref-type="fig"}). Quantification revealed 32% more microglia coverage in saline-injected *IL-6*-/- mice vs. WT mice (*p* \< 0.05; Figure [6F](#F6){ref-type="fig"}). IOP elevation decreased microglia coverage by 45% in WT retina (*p* \< 0.05; Figure [6F](#F6){ref-type="fig"}), as compared to saline-injected controls (Figure [6F](#F6){ref-type="fig"}). While it appeared as if there was decreased microglial coverage in *IL-6*-/- retina following IOP elevation compared to saline-injected controls, it did not reach statistical significance (*p* \> 0.05; Figure [6F](#F6){ref-type="fig"}). Additionally, microglia coverage remained higher in *IL-6*-/- mice than in WT mice following IOP elevation (*p* \< 0.05, Figure [6F](#F6){ref-type="fig"}). Based on qualitative assessment, IOP-induced changes in percent area coverage appeared to arise from changes in microglia density (Figure [6D](#F6){ref-type="fig"}). To quantitatively test this observation, we measured the density of Iba-1+ microglia across all experimental groups. We found that microbead-induced IOP elevation decreased the density of microglia by 37% in WT retina (*p* \< 0.05) and by 36% in *IL-6*-/- mice (*p* \< 0.05), as compared to saline-injected controls (Figure [6G](#F6){ref-type="fig"}). There was no significant difference in the density of microglia between WT and *IL-6*-/- mice regardless of treatment (*p* \> 0.05; Figure [6G](#F6){ref-type="fig"}).

![IL-6 deficiency affects microglial coverage regardless of IOP. **(A,B)** Representative 60X confocal images depicting quantification of percent coverage of GFAP+ astrocytes (green; **A**, left) and Iba-1+ microglia (green; **B**, left). The area containing above background signal for GFAP and Iba-1 was highlighted in red (**A,B**; right) and divided against the total area of the image to obtain the percent coverage measurements. **(C,D)** Representative 60X confocal images depicting GFAP+ astrocyte (green; **C**) and Iba-1+ microglia (green; **D**) labeling in whole mount retina of microbead- and saline- injected WT and *IL-6*-/- eyes. **(E)** Boxplot of percent coverage of GFAP+ astrocytes in saline (white) and microbead (gray) injected WT (left) and *IL-6*-/- (right) eyes. No genotype or IOP dependent changes were calculated. **(F)** Boxplot of percent coverage of Iba-1+ microglia in saline- (white) and microbead- (gray) injected WT (left) and *IL-6*-/- (right) eyes. While an IL-6 dependent increase in percent coverage of microglia is seen in both saline and microbead- injected eyes, only an IOP dependent decrease is seen in microbead- injected WT eyes. **(G)** Boxplot of Iba-1+ microglia cell density (counts/mm^2^) in saline- (white) and microbead- (gray) injected WT (left) and *IL-6*-/- (right) eyes. IOP dependent decreases in microglia counts are evident in microbead- injected eyes are evident in both WT and *IL-6*-/- eyes. ^\*^*p* \< 0.05. *n* = 6--8 images/eye/condition/genotype. Scale bars= 30 μm for all images. Dashed lines in boxplot indicate median value of data set.](fnins-11-00318-g0006){#F6}

Discussion {#s4}
==========

The present work investigated the relevance of IL-6 signaling to RGC axonopathy following microbead-induced IOP elevation. By comparing functional and structural outcomes of RGC degeneration in *IL-6*-/- and WT mice, we were able to link IL-6 signaling with specific events in RGC axonopathy. These studies delineate a role for IL-6 in the progression from functional deficits to structural degeneration within the axonopathy continuum. Secondarily, our data also indicated a role for IL-6 in corneal wound healing and potentially, IOP regulation.

Glaucoma is associated with elevated IOP. Current therapies, directed toward lowering IOP, delay pathology (Calkins, [@B10]). Not surprisingly, animal models of glaucoma are generally characterized by elevated IOP and subsequent degeneration of RGCs. Despite modest differences in baseline IOP, the magnitude of IOP elevation achieved with microbead occlusion was identical in WT and *IL-6*-/- mice (Figure [1](#F1){ref-type="fig"}). This indicates that IL-6 deficiency does not impact efficacy of IOP elevation in this model. Intracameral injection of saline and microbeads requires a small diameter (approx. 100 μm) puncture in the cornea. OCT imaging revealed that IL-6 deficiency resulted in a larger corneal wound and impeded stitching and filling of the stromal and endothelial layers of the cornea, which was visible in WT mice within 2 weeks of puncture (Figure [5](#F5){ref-type="fig"}). Interestingly, the epithelial layer of the cornea in *IL-6*-/- mice was indistinguishable from WT mice (Figure [5](#F5){ref-type="fig"}). This suggests that IL-6 signaling plays a prominent role in healing of stromal and endothelial, but not epithelial, layers of cornea. That a deficit in corneal wound healing was noted in our studies is not surprising, as IL-6 is strongly associated with wound healing and tissue regeneration in other systems (Blindenbacher et al., [@B2]; Lin et al., [@B42]; Tiberio et al., [@B64]; McFarland-Mancini et al., [@B46]).

Structural degeneration of the optic nerve and vision loss are the two hallmarks of glaucoma. In our study, IL-6 deficiency preserved both the structure of RGC axons and visual acuity following 8 weeks of elevated IOP. Consistent with previous findings (Sappington et al., [@B56]; Lambert et al., [@B39]; Ward et al., [@B68]; Bond et al., [@B4]), microbead-induced IOP elevation decreased axon density, while increasing degenerative axon profiles and macrogliosis in WT optic nerves (Figure [2](#F2){ref-type="fig"}). This was accompanied by a significant and IOP-dependent decrease in visual acuity (Figure [4](#F4){ref-type="fig"}). In contrast, *IL-6*-/- mice exhibited no *IOP-dependent* changes in visual acuity (Figure [4](#F4){ref-type="fig"}) or optic nerve outcomes, including axon density, degenerative axon profiles or macrogliosis (Figure [2](#F2){ref-type="fig"}). However, visual acuity decreased modestly, but significantly (8%), in an *IOP-independent* manner following both saline and microbead injection in *IL-6*-/- mice (Figure [4](#F4){ref-type="fig"}). That this decrease was noted following both types of injection and did not change over time, it is highly likely that visual acuity was negatively impacted by the observed deficits in corneal wound healing (Figure [5](#F5){ref-type="fig"}). Together, these data indicate that IL-6 signaling impacts RGC axonopathy prior to the onset of both structural degeneration and decreased visual function.

Previous studies indicate that RGC axonopathy in glaucoma progresses in a distal to proximal fashion and that deficits in active, anterograde transport precede structural degeneration of the optic nerve (Crish et al., [@B19], [@B18]). Consistent with previously published studies (Sappington et al., [@B56]; Lambert et al., [@B39]; Ward et al., [@B68]; Bond et al., [@B4]), microbead-induced IOP elevation in WT mice resulted in a 50% decrease in anterograde transport of CTB to the SC (Figure [3](#F3){ref-type="fig"}). Interestingly, *IL-6*-/- mice exhibited a similar decrease in anterograde transport (Figure [3](#F3){ref-type="fig"}). This suggests that IL-6 signaling does not play a significant role in the development of axon pathology that leads to deficits in axon transport. Together with the optic nerve and visual function analyses, these data delineate a temporal window in which IL-6 signaling contributes to RGC axonopathy. Specifically, this temporal window begins after the onset of axon transport deficits and prior to the onset of structural degeneration and decreased visual function. More generally, our data suggest that axon transport deficits and structural degeneration of axons occurs via, at least partially, independent mechanisms.

Given that IL-6 is typically associated with inflammatory functions, we assessed microglia and astrocyte reactivity in the GCL and NFL. Not surprisingly, our analysis revealed a strong association between IOP, IL-6, and microglia, the "resident" immune cell of the CNS. Elevated IOP decreased microglia coverage in the GCL/NFL of WT mice (Figure [6](#F6){ref-type="fig"}). This was attributable to a decrease in the density of microglia (Figure [6](#F6){ref-type="fig"}). Interestingly, elevated IOP also decreased the density of microglia in *IL-6*-/- mice, but did not sufficiently reduce microglia coverage to a statistically significant level (Figure [6](#F6){ref-type="fig"}). Microglia coverage was greater in *IL-6*-/- than in WT mice, regardless of IOP (Figure [6](#F6){ref-type="fig"}). This IL-6-dependent increase in microglia coverage was not attributable to changes in microglia density, suggesting that it likely arises from changes in size and extent of ramification. Based on previous literature, changes in microglia density likely arise from migration of microglia to other retinal layers, particularly the outer retina (Rojas et al., [@B53]). These findings suggest that IL-6 may be more relevant for microglia ramification/activation state than microglia migration or temporal onset of microglia reactivity in this model. Unlike microglia, astrocyte reactivity did not appear to associate with IOP elevation or IL-6 deficiency (Figure [6](#F6){ref-type="fig"}). The former is contrary to studies of astrocyte reactivity in other glaucoma models, where both retinal astrocyte hypertrophy and hypotrophy are associated with elevated IOP. Notably, most of these studies were conducted in either chronic models (Inman and Horner, [@B34]; Formichella et al., [@B29]) or inducible models with much higher IOP elevation (Wang et al., [@B67]; Gallego et al., [@B30]). Differences in the duration and magnitude of IOP elevation, as well as severity of RGC pathology, could account for our contradictory findings. Together, these data suggest that IL-6 signaling generally associates with microglia rather than astrocytes. This is supported by our previous work indicating that retinal microglia, but not retinal astrocytes, induce IL-6 expression in response to elevated pressure (Sappington and Calkins, [@B54], [@B55]; Sappington et al., [@B57]).

While our findings support a role for IL-6 in the progression RGC degeneration in glaucoma, we utilized *IL-6*-/- mice that are generated from homozygous pairing. As such, these mice are deficient in IL-6 throughout development as well as in adulthood. In this case, we are unable to differentiate IL-6-dependent outcomes arising from IL-6 signaling during disease and those arising from developmental IL-6 signaling. Our findings indicate that there are at least two developmental ramifications pertinent to our investigation:

First, IL-6 deficiency modestly, but significantly, decreased baseline IOP by \~4% compared to WT (Figure [1](#F1){ref-type="fig"}). There is some indication that modulation of IL-6 signaling accompanies IOP elevations in human patients, including both primary open angle and angle closure glaucoma (Takai et al., [@B62]; Engel et al., [@B25]; Huang et al., [@B33]; Du et al., [@B22]). However, in a recent study of porcine anterior segment, IL-6 did not appear to alter outflow facility that determines IOP (Birke et al., [@B1]). Our data suggest that, at least in mice, IL-6 signaling may impact the IOP "set-point" either through modulation of aqueous dynamics or during development of the anterior chamber. That the relative increase in IOP achieved with microbeads was equivalent in WT and *IL-6*-/- mice indicates the latter may be more relevant. Most importantly, the magnitude of change in IOP, rather than absolute IOP, appears to be of greater import for disease etiology in both animal models and human patients. In humans, IOP fluctuations, defined as the difference between the highest and lowest IOP, is greater in glaucoma patients than non-glaucoma patients (Nouri-Mahdavi et al., [@B48]; Sihota et al., [@B58]; De Moraes et al., [@B20]; Tan et al., [@B63]; Tojo et al., [@B65]) and is predictive of glaucoma progression (Nouri-Mahdavi et al., [@B48]; Sihota et al., [@B58]). Likewise, the magnitude of peak IOP measurement predicts progression in glaucoma patients, even for those with IOP successfully lowered by conventional treatments (Nouri-Mahdavi et al., [@B48]). In animal models, IOP elevations are often presented as a change in cumulative IOP, which documents the change in IOP from control eyes or baseline over time. This measure is well-documented as a strong predictor of RGC pathology (Gao and Jakobs, [@B31]). Additional studies of strain differences indicate that absolute IOP does not necessarily correlate with RGC pathology (Cone et al., [@B16], [@B17]). In these studies, some strains present with less severity despite higher IOP elevations on the order of several mmHg (Cone et al., [@B16], [@B17]). In our studies, the strain background is controlled and thus, also is the potential for susceptibility defined by this background. As such, it is unlikely that differences in disease outcomes noted in our *IL-6*-/- mice are attributable to the 0.7 mmHg difference in absolute IOP and likely arise from other IL-6-dependent outcomes.

Second, baseline axon density in the optic nerve of *IL-6*-/- mice was approximately 15% lower than that of WT mice. Our assessment of axon density in PPD-stained semi-thin sections allows counting of only myelinated axons. Previous literature documents that IL-6 influences oligodendrocyte differentiation and gene expression associated with myelination *in vitro* (Valerio et al., [@B66]; Zhang et al., [@B71], [@B72]). As such, it is probable that myelination of RGC axons is altered in our *IL-6*-/- mice. This may or may not have consequences beyond confounding axon density measurements. Further studies with conditional perturbation of IL-6 signaling will be needed to elucidate the source and impact of confounds arising from developmental deficiency of IL-6 signaling.

In conclusion, our findings indicate that IL-6 is part of a mechanism that specifically leads to structural degeneration of axons. Furthermore, its absence is sufficient to prevent both structural degeneration of the optic nerve and vision loss. That the functional and structural components of RGC axonopathy could be mechanistically separated has tremendous implications for therapeutic targeting, and our findings identify IL-6 as a potential candidate for such.
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IL-6

:   interleukin-6

IOP

:   intraocular pressure

CNS

:   central nervous system

RGC

:   retinal ganglion cell

GCL

:   ganglion cell layer

NFL

:   nerve fiber layer

SC

:   superior colliculus

GFAP

:   glial fibrillary acidic protein

Iba-1

:   ionized calcium-binding adapter molecule-1

CTB

:   cholera toxin beta-subunit
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[^1]: Edited by: Jason R. Richardson, Northeast Ohio Medical University, United States

[^2]: Reviewed by: Varun Kesherwani, University of Nebraska Medical Center, United States; Gregory W. J. Hawryluk, University of Utah, United States; Jena J. Steinle, Wayne State University School of Medicine, United States

[^3]: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
